stockrow
Monday 9 November 2026
Export ABOS’s income statement to Excel — free account
Acumen Pharmaceuticals, Inc.
ABOS- EPS
- +20.3%
- Free cash flow
- +12.6%
- Total debt
- −14.3%
Quarter to September 2026, against a year earlier
0.22
0.01
+4.76%
Follow ABOS
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
| (162.72%) | (120.50%) | (93.23%) | (96.20%) |
+8 more TTM periods Free account |
|
| (91.28%) | (72.97%) | (67.01%) | (67.07%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(259.60%) | (152.98%) | (109.06%) | (131.54%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.22) | (1.27) | (1.67) | (1.91) | |
Free Cash Flow |
(87.95) | (91.79) | (105.54) | (115.63) | |
Capital Expenditures |
— | — | — | (0.09) | |
| Other line items | |||||
Cash ROIC |
(63.05%) | (46.12%) | (42.74%) | (52.93%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(24.65) | (24.41) | (26.84) | (29.32) | |
Operating CF/Net income |
0.85 | 0.87 | 0.93 | 0.95 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.14 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.22) | (1.27) | (1.67) | (1.91) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | — | — | 0.00 |
Columns are period end dates · fundamentals updated 2 Nov 2026